JP Morgan Chase’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

JP Morgan Chase’s Portfolio PBLA Stock Details PBLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-623	Closed	-$11.4K	–	8119
2023 Q4	$11.4K	Buy	+623	New	+$9.75K	﹤0.01%	6373

JP Morgan Chase's PBLA Position: Q1 2024 in Review

JP Morgan Chase sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q1 2024, closing a stake of 623 shares — an estimated $11.4K sold.

JP Morgan Chase first reported a position in PBLA in Q4 2023 and held it in 1 quarter. The position peaked at $11.4K in Q4 2023. 0 funds tracked by Wall St. Rank hold PBLA as of Q1 2024.

JP Morgan Chase reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
JP Morgan Chase sold 623 Panbela Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $11.4K.
JP Morgan Chase first reported a position in Panbela Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
JP Morgan Chase's Panbela Therapeutics, Inc. Common Stock position peaked at $11.4K in Q4 2023.
0 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.